OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Revenue of OmniAb, Inc. (OABI)
Revenue in 2023 (TTM): $34.16 M
According to OmniAb, Inc.'s latest financial reports the company's current revenue (TTM) is $34.16 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of OmniAb, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $34.16 M | $14.67 M | $-49,731,000 | $-64,363,000 | $-50,619,000 |
| 2022 | $59.08 M | $42.83 M | $-13,011,000 | $-26,061,000 | $-22,334,000 |
| 2021 | $34.75 M | $19.78 M | $-18,091,000 | $-34,350,000 | $-27,042,000 |
| 2020 | $23.27 M | $23.27 M | $-10,586,000 | $-23,728,000 | $-17,557,000 |
| 2019 | $18.32 M | $18.32 M | $-2,110,000 | $-13,027,000 | $-13,589,000 |